版本:
中国

BRIEF-GSK has one hit, one miss with mepolizumab in Phase III COPD studies

May 10 Glaxosmithkline

* Says one study misses, one hits statistical significance testing mepolizumab in patients with severe chronic obstructive pulmonary disease Source text for Eikon: Further company coverage: (Reporting by UK bureau)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐